 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. The study is being conducted at the Aflac Cancer and Blood Disorders Center of Childrens Healthcare of Atlanta. 